



pharmaceuticals ltd.

Registered & Corporate Office :

Plot No. 19-111, Road No. 71,
Opp. Bharatiya Vidya Bhavan Public School,
Jubilee Hills Hyderabad - 500 096, Telangana. INDIA,
Tel : +91-40-6628 8888, Fax : +91-40-2355 1402
CIN : L24239AP1987PLC008066
Email : info@smspharma.com, www.smspharma.com

Date: 05th November, 2016

To,
The Managers,
Corporate Filings Department,
Bombay Stock Exchange Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400 001

The Managers,
Listing Compliance Department,
National Stock Exchange of India Ltd.
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E),
Mumbai - 400 051.

Security Code: 532815

Symbol: SMSPHARMA

Subject: Outcome of the Board Meeting held on 05th November, 2016.

Dear Sir/Madam,

With reference to the subject cited above, please note that the Board of Directors of the Company at their meeting held today have inter alia considered and approved/adopted the Standalone Unaudited financial results for the quarter ended on 30th September, 2016 along with Limited Review Report.

We are enclosing herewith the Standalone unaudited financial results for the quarter ended on 30th September, 2016 as approved by the Board along with the Limited Review Report.

Please take the above intimation on your records.

Yours Faithfully,

For SMS Pharmaceuticals Limited

Thirumalesh Tumma
Company Secretary

SMS PHARMACEUTICAL LIMITED

Regd. Office: Plot No.19-III, Opp. BVBP School, Road No.71, Jubilee Hills, Hyderabad - 500 096

Un-Audited Financial Results for the Quarter and Six months Ended 30th September, 2016

S.No.	Particulars	Quarter Ended			Half Year Ended		(Rs. In Lakhs)
		30-09-2016 (Unaudited)	30-06-2016 (Unaudited)	30-09-2015 (Unaudited)	30-09-2016 (Unaudited)	30-09-2015 (Unaudited)	Year Ended 31-03-2016 Audited
1	Income from Operations						
	(a) Net sales/Income from Operations	16,801.17	13,737.01	14,183.82	30,538.18	25,506.12	55,607.10
	(b) Other Operating Income	1,042.54	848.13	1,089.53	1,890.67	2,162.42	4,712.24
	Total Income from Operations (net)	17,843.71	14,585.14	15,273.35	32,428.85	27,668.54	60,319.34
2	Expenses						
	(a) Cost of materials consumed	11,116.00	10,311.10	10,728.71	21,427.11	18,852.68	39,945.32
	(b) Purchases of stock-in-trade	716.44	(1,229.37)	(727.89)	(512.94)	(984.67)	(963.93)
	(c) Changes in inventories of finished goods work-in-progress and stock-in trade						
	(d) Employee Benefits Expense	1,041.92	1,010.80	928.31	2,052.72	1,810.33	3,811.31
	(e) Depreciation and amortisation expense	621.80	611.88	474.09	1,233.68	939.35	1,943.30
	(f) Other expenses	2,138.50	2,091.52	2,088.41	4,230.02	3,940.47	8,607.08
	Total - (a to f)	15,634.66	12,795.93	13,491.62	28,430.59	24,558.16	53,343.08
3	Profit from Operations before Other Income, finance cost and Exceptional Items	2,209.05	1,789.21	1,781.73	3,998.26	3,110.38	6,976.26
4	(1) - (2)	71.08	31.19	18.92	102.27	57.89	360.79
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3)+(4)	2,280.13	1,820.40	1,800.65	4,100.53	3,168.27	7,337.05
6	Finance costs	538.35	560.96	431.82	1,099.30	879.65	1,709.81
7	Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5)+(6)	1,741.78	1,259.44	1,368.83	3,001.23	2,288.62	5,627.24
8	Exceptional items						
9	Profit / (Loss) from Ordinary Activities before Tax (7)+(8)	1,741.78	1,259.44	1,368.83	3,001.23	2,288.62	5,627.24
10	Tax Expenses	609.50	344.14	320.00	953.64	520.00	1,453.32
11	Net Profit / (Loss) from ordinary activities after Tax (9)-(10)	1,132.28	915.30	1,048.83	2,047.59	1,768.62	4,163.92
12	Extraordinary items (net of Tax Expense Rs. ... in lakhs)						
13	Net Profit / (Loss) for the period (11) -(12)	1,132.28	915.30	1,048.83	2,047.59	1,768.62	4,163.92
14	Share of profit / (loss) of associates*						
15	Minority Interest*						
16	Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13+14+15)*	1,132.28	915.30	1,048.83	2,047.59	1,768.62	4,163.92
17	Paid-up equity share capital Rs.1/- per share	84,652,030	84,652,030	8,465,203	84,652,030	8,465,203	84,652,030
18	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	-	-	28,589.63
19.i	Earning Per Share (before extraordinary items) (of Rs...../ each) (not annualised)	1.34	1.08	1.24	2.42	2.09	4.92
19.ii	Earning Per Share (after extraordinary items) (of Rs...../ each) (not annualised)	1.34	1.08	1.24	2.42	2.09	4.92



Statement of Assets & Liabilities as at 30th September, 2016

(Rs.in Lakhs)




Sr.No.	Particulars	As at 30.09.2016 (Unaudited)	As at 31.03.2016 Audited
A	<u>EQUITY AND LIABILITIES</u>		
1	Shareholders' Funds		
	(a) Share Capital	846.52	846.52
	(b) Reserves & Surplus	30,637.21	28,589.63
	Sub-Total -Shareholders' funds	31,483.73	29,436.15
2	Non-Current Liabilities		
	(a) Long Term Borrowings	10,339.22	11,322.50
	(b) Deferred Tax Liability (Net)	4,793.67	4,490.03
	(c) Long Term Provisions	343.38	343.38
	Sub-Total -Non-Current Liabilities	15,476.27	16,155.91
3	Current Liabilities		
	(a) Short Term Borrowings	5,320.11	7,274.74
	(b) Trade Payables	15,029.68	8,440.29
	(c) Other Current Liabilities	3,670.81	4,037.40
	(d) Short Term Provisions	290.11	290.11
	Sub-Total - Current Liabilities	24,310.71	20,042.54
	TOTAL - EQUITY AND LIABILITIES	71,270.71	65,634.60
B	<u>ASSETS</u>		
1	Non-Current Assets		
	(a) Fixed Assets	38,258.40	38,315.07
	(b) Non Current Investments	2,817.94	2,126.90
	(c) Long Term Loans & Advances	694.09	437.40
	Sub-Total - Non-Current Assets	41,770.43	40,879.37
2	Current Assets		
	(a) Inventories	10,403.14	11,268.37
	(b) Trade Receivables	12,639.97	6,108.77
	(c) Cash and Cash Equivalents	703.40	1,508.24
	(d) Short Term Loans & Advances	2,013.09	2,251.97
	(e) Other Current Assets	3,740.68	3,617.88
	Sub-Total - Current Assets	29,500.28	24,755.23
	TOTAL ASSETS	71,270.71	65,634.60

Notes:

1. The above results were reviewed by the Audit Committee on 5th November, 2016 and taken on record by the Board of Directors at its meeting held on 5th November, 2016 and "Limited Review" of the same has been carried out by the Statutory Auditors of the company.
2. The Company's business activity falls within a single primary business segment. Hence segment reporting is not applicable.
3. During the 3rd quarter of 2015-16, the equity shares having face value of Rs.10/- each has been sub-divided into Rs.1/- each, accordingly the number of shares and earnings per share for the previous period/quarters have been restated
4. Both Sundry Creditors and Sundry Debtors are stated at gross value i.e. they include credit transactions of debtors and debit transactions of creditors respectively relating to same party.
5. All accounting policies are followed consistently subject to accounting treatment of Debtors and Creditors as stated in Note no 4 above.
6. Figures of previous periods have been regrouped / rearranged wherever necessary.

Place: Hyderabad
Date : 05-11-2016

For SMS Pharmaceuticals Limited



Ramesh Babu Potluri

Ramesh Babu Potluri
Chairman & Managing Director

Limited Review Report

To
The Board of Directors
SMS PHARMACEUTICALS LIMITED
Hyderabad.


We have reviewed the accompanying statement of unaudited financial results of SMS PHARMACEUTICALS LIMITED for the quarter ended 30th September 2016. The statement has been prepared by the company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (The "Listing Regulations, 2015") which has been initialized by us for identification purposes. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by Independent Auditor of Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Accounting standards, prescribed under Sec.133 of Companies Act, 2013, read with rule 7 of the companies (Accounts) Rules, 2014 and Accounting standard 30, Financial Instruments. Recognition and Measurement issued by the Institute of Chartered Accountants of India to the extent it does not contradict any other accounting standard referred to in section 133 of the companies Act read with Rule 7 of Companies (Accounts) Rules, 2014 and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of regulation 33 of the Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hyderabad
Date: 05-11-2016

For RAMBABU & CO.,
Chartered Accountants
Reg. No. 002976S


GVL PRASAD
Partner
M. No. 026548

